The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Large Will The Pruritus Therapeutic Market Be By 2030 Compared To Its 2026 Market Size?
The pruritus therapeutic market size has demonstrated significant growth in recent years. It is expected to expand from $15.38 billion in 2025 to $16.76 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.0%. The increase observed in the historic period can be attributed to the rising prevalence of dermatological and systemic conditions, the wider adoption of antihistamines and corticosteroids, the expansion of outpatient dermatology services, growing patient awareness concerning itch-related disorders, and the availability of diverse therapeutic options.
The pruritus therapeutic market is projected to experience substantial expansion in the coming years. By 2030, this market is anticipated to reach $24.04 billion, exhibiting a compound annual growth rate (CAGR) of 9.4%. This projected growth during the forecast period stems from several factors, including escalating investment in new itch-modulating treatments, a heightened emphasis on individualized pruritus care, the broadening of pipelines for biologic and immunomodulatory drugs, an increasing need for non-steroidal options, and greater clinical research efforts. Key trends during this period are expected to encompass the accelerated development of specific antipruritic medications, increased uptake of combined drug regimens, a stronger focus on managing disease-specific pruritus, the proliferation of advanced topical applications, and a reinforced commitment to sustained symptom alleviation.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9925&type=smp
What Leading Drivers Are Supporting The Pruritus Therapeutic Market Expansion?
The rising occurrence of Chronic Kidney Disease (CKD) is anticipated to propel the expansion of the pruritus therapeutic market in the coming years. Chronic Kidney Disease (CKD) is characterized as a long-term medical condition where the kidneys gradually diminish their ability to function correctly and is categorized into five severity levels. Pruritus, commonly known as itching, stands as a frequent symptom associated with Chronic Kidney Disease (CKD). While the precise processes are not fully understood, pruritus in CKD can stem from a variety of reasons. For example, according to Kidney Research UK, a UK-based charitable organization focused on kidney disease research and advocacy, data from June 2023 indicated that approximately 7.19 million individuals in the UK were impacted by Chronic Kidney Disease in 2023, constituting over 10% of the UK population. This number is projected to climb to 7.61 million people by 2033. Consequently, the increasing incidence of Chronic Kidney Disease is a key driver for the pruritus therapeutic market.
Which Segments Define The Pruritus Therapeutic Market Segment Structure?
The pruritus therapeutic market covered in this report is segmented –
1) By Type: Corticosteroids, Antihistamines, Local Anesthetics, Counterirritants, Immunosuppressant, Calcineurin Inhibitors, Others Types
2) By Disease Type: Atopic Dermatitis Or Eczema, Allergic Contact Dermatitis, Urticaria, Cutaneous T-Cell, Other Disease Types
3) By Application: External Use, Oral, Injection
4) By End Use: Hospitals, Clinics, Other Uses
Subsegments:
1) By Corticosteroids: Topical Corticosteroids, Systemic Corticosteroids
2) By Antihistamines: First-Generation Antihistamines, Second-Generation Antihistamines
3) By Local Anesthetics: Topical Local Anesthetics, Injectable Local Anesthetics
4) By Counterirritants: Menthol-Based Products, Camphor-Based Products
5) By Immunosuppressants: Systemic Immunosuppressants, Topical Immunosuppressants
6) By Calcineurin Inhibitors: Tacrolimus, Pimecrolimus
7) By Other Types: Antidepressants, Phototherapy Treatments, Biologic And Targeted Therapies
What Emerging Trends Are Seen In The Pruritus Therapeutic Market?
Leading companies in the pruritus therapeutic market are adopting a strategic partnership approach, with the goal of addressing moderate-to-severe atopic dermatitis. These strategic partnerships involve businesses leveraging each other’s strengths and resources to achieve mutual benefits and success. For instance, in January 2023, Amgen Inc., a US-based biopharmaceutical company, in collaboration with Kyowa Kirin, is investigating rocatinlimab (AMG 451/KHK4083), which is a potential first-in-class anti-OX40 monoclonal antibody currently being studied for individuals with moderate to severe atopic dermatitis. Amgen and Kyowa Kirin have recently started enrolling participants in a worldwide Phase 3 trial, called ROCKET, to evaluate the safety and effectiveness of rocatinlimab in diverse moderate-to-severe atopic dermatitis patients who have a high disease burden. The ROCKET Phase 3 program comprises seven worldwide investigations. Kyowa Kirin Co., Ltd. is a Japan-based pharmaceutical and biotechnology company.
Who Are The Established Players Within The Pruritus Therapeutic Market?
Major companies operating in the pruritus therapeutic market are Astellas Pharma Inc., Bristol Myers Squibb Company, Cipla Inc., Eli Lilly And Company, Galderma Laboratories LP, GlaxoSmithKline plc, Merck And Co. Inc., Novartis AG, Pfizer Inc., Sanofi SA, Abbott Laboratories, Almirall SA, Eisai Co. Ltd., Glenmark Pharmaceuticals Ltd., Ipca Laboratories Ltd., Lupin Chemicals Ltd., Cara Therapeutics Inc., EPI Health LLC, AbbVie Inc., Bayer AG, Bausch Health Companies Inc., Regeneron Pharmaceuticals Inc., Huapont Life Sciences Co. Ltd., LEO Pharma AS, MC2 Therapeutics Ltd., Novan Inc., Trevi Therapeutics Inc., UCB SA, Viatris Inc., Teva Pharmaceutical Industries Ltd.
Get The Full Pruritus Therapeutic Market Report:
https://www.thebusinessresearchcompany.com/report/pruritus-therapeutic-global-market-report
Where Is The Pruritus Therapeutic Market Primarily Concentrated By Region?
North America was the largest region in the pruritus therapeutic market in 2025. The regions covered in the pruritus therapeutic market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Pruritus Therapeutic Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/pruritus-therapeutic-global-market-report
Browse Through More Reports Similar to the Global Pruritus Therapeutic Market 2026, By The Business Research Company
Pruritus Therapeutics Market Report 2026
https://www.thebusinessresearchcompany.com/report/pruritus-therapeutics-global-market-report
Tinea Pedis Treatment Market Report
https://www.thebusinessresearchcompany.com/report/tinea-pedis-treatment-global-market-report
Vitiligo Treatment Market Report
https://www.thebusinessresearchcompany.com/report/vitiligo-treatment-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model